Formatech, Inc. to Donate Services to Manufacture KAI Pharmaceuticals, Inc.'s Clinical Candidate Under Its "Fillanthropy(TM) Program"
Published: Nov 18, 2009
ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program. KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.